From peptides to non-peptide peptidomimetics: Design and synthesis of new piperidine inhibitors of aspartic peptidases

Organic Letters

Volumn 3, Issue 15, 2001, Pages 2317-2320

  Bursavich, Matthew G ^a   West, Chris W ^a   Rich, Daniel H ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; PEPSIN A; PIPERIDINE DERIVATIVE; PROTEINASE INHIBITOR; RENIN; RHIZOPUSPEPSIN;

ANIMAL; ARTICLE; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; PROTEIN SECONDARY STRUCTURE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SWINE; SYNTHESIS;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BINDING SITES; PEPSIN A; PIPERIDINES; PROTEASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; RENIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 0035954893     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol016092u     Document Type: Article

References (39)

1. Leung, D.; Abbenante, G.; Fairlie, D. P. J. Med. Chem. 2000, 43, 305.
2. Rich, D. H. Peptidase Inhibitors. In Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds; Hansch, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: 1990; pp 391-441.
3. Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359.
4. Lebon, F.; Ledecq, M. Curr. Med. Chem. 2000, 7, 455.
5. Smith, A. B., III.; Hirschmann, R.; Pasternak, A.; Guzman, M. C.; Yokoyama, A.; Sprengeler, P. A.; Darke, P. L.; Emini, E. A.; Schleif, W. A. J. Am. Chem. Soc. 1995, 177, 11113.
6. Fairlie D. P.; Tyndall, J. D. A.; Reid, R. C.; Wong, A. K.; Abbenante, G.; Scanlon, M. J.; March, D. R.; Bergman, D. A.; Chai, C. L. L.; Burkett, B. A. J. Med. Chem. 2000, 43, 1271.
7. For definitions of different types of peptidomimetics, see: Ripka, A. S.; Rich, D. H. Curr. Opin. Chem. Biol. 1998, 2, 439.
8. Wiley: R. A.; Rich, D. H. Med. Res. Rev. 1993, 13, 327.
9. Freidinger, R. M. Curr. Opin. Chem. Biol. 1999, 3, 395.
10. Turner, S. R.; Strohbach,: J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, R. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M.-M.; Lynn, J. C.; Chong, K. T.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisnvongs, S. J. Med. Chem.
11. Hagen, S.; Vara Prasad, J. V. N.; Tait, B. D. Adv. Med. Chem. 2000, 5, 159.
12. For the original definition of non-peptide peptidomimetic, see: Farmer P. S. In Drug Design; Ariens, E. J., Ed.; Academic Press: New York 1980; Vol. 10, p 119. However, those HIV protease inhibitors in refs 3-5 that do not contain a dipeptide unit are a different type of non-peptide peptidomimetic.
13. Lam, P. Y.-S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Run, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Vitanen,
14. Bohacek, R. S.; McMartin, C.; Guida, W. C. Med. Res. Rev. 1996, 16, 3.
15. (a) Oefner, C.; Binggeli, A.; Breu, V.; Bur, D.; Clozel, J.P.; D'arcy, A.; Dorn, A.; Fischli, W.; Gruninger, F.; Guller, R.; Hirth, G.; Marki, H.; Mathews, S.; Miller, M.; Ridley, R. G.; Stadler, H.; Viera, E.; Wilhelm, M.; Winkler, F.; Wostl, W. Chem. Biol. 1999, 6, 127.
16. (b) Viera, E.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Güller, R.; Hirth, G.; Märki, H. P.; Müller, M.; Oefner, C.; Scalone, M.; Stadler, H.; Wilhelm, M.; Wostl, W. Bioorg. Med. Chem. Let. 1999, 9, 1397.
17. (c) Güller, R.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Hirth, G.; Jenny, C.; Kansy, M.; Montavon, F.; Müller, M.; Oefner, C.; Stadler, H.; Vieira, E.; Wilhelm, M.; Wostl, W.; Märki, P. Bioorg. Med. Chem. Let. 1999, 9, 1403.
18. Rich, D. H. J. Med. Chem. 1985, 28, 263.
19. (a) Jones, D. M.; Sueiras-Diaz, J.; Szelke, M.; Leckie, B.J.; Beattie, S. R.; Morton, J.; Neidle, S.; Kuroda, R. J. Pept. Res. 1997, 50, 109.
20. (b) Sueiras-Diaz, J.; Jones, D. M.; Szelke, M.; Leckie, B. J.; Beattie, C.; Morton, J. J. Pept. Res. 1997, 50, 239.
21. (a) Ripka, A. S.; Satyshur, K. A.; Bohacek, R. S.; Rich, D. H. Org. Lett 2001, 3, 2309.
22. (b) Dales, N. A.; Satyshur, K. A.; Bohacek, R. S.; Rich, D. H. Org. Lett. 2001, 3, 2313.
23. i = 320 nM against porcine pepsin.
24. The same process was carried out with R. chinensis pepsin.
25. (a) Hsu, I-N.; Delbaere, L. T.J.; James, M. N. G.; Hofmann, T. Nature 1977, 40, 233.
26. (b) James, M. N. G.; Sielecki, A.; Salituro, F.; Rich, D. H.; Hofmann, T. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 6137.
27. -1.
28. Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K.-S.; Kwong, H. L.; Morikawa, K.; Wang, Z. M.; Xu, D.; Zhang, X. L. J. Org. Chem.1992, 57, 2768.
29. Synthesis of the related trans-2-phenylcyclohexanol: King, S. B.; Sharpless, K. B. Tetrahedron Lett. 1994, 35, 5611.
30. Wustriw, D. J.; Wise, L.D. Synthesis 1991, 993.
31. The silyl-ether analogue did not react presumably for steric reasons; other ether analogues underwent reductive cleavage of the C4′ C-O bond.
32. See Figure 7 in Supporting Information.
33. (a) Flentke, G. R.; Glinski, J.; Satyshur, K.; Rich, D. H. Protein Expression Purif. 1999. 16, 213.
34. (b) Peranteau, A. G.; Kuzmic, P.; Angell, Y.; Rich, D. H. Anal. Biochem. 1995, 227, 242.
35. Rich, D. H.; Bohacek, R. S.; Dales, N. A.; Glunz, P.; Ripka, A. S. Chimia 1997, 51, 45.
36. Kumar, S.; Ma, B.; Tsai, C.-J.; Sinha, N.; Nussinov, R. Protein Sci. 2000, 9, 10.
37. Todd, M. J.; Freire, E. Proteins: Struct., Funct., Gene. 1999, 36, 147.
38. Programs to perform these calculations have not been reported to date, but seem possible.
39. For structural comparison, see Figure 8 in Supporting Information.